ArticleReproductive biology and endocrinology : RB&E2025
Semenogelin I-derived peptide SgI-52 binds membrane Peroxiredoxin 6 and induces oxidative stress in asthenozoospermic sperm.
Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfertility is a global health concern, with asthenozoospermia (AZS) being a common male factor. Our previous research demonstrated that the semenogelin I-derived peptide SgI-52 (SgI-52) binds more rapidly and extensively to demembranated sperm and AZS sperm, significantly inhibiting sperm motility and impairing mitochondrial function. However, the specific molecular targets of SgI-52 on sperm and the mechanisms by which it modulates oxidative stress and sperm function remain unclear. This study therefore investigates the interactions of SgI-52 with sperm surface proteins and its impact on oxidative stress.
methodsSperm proteins from AZS donors were extracted to identify SgI-52 targets using affinity chromatography and quantitative proteomics. The interaction with PRDX 6 was analyzed using AlphaFold 3 predictions and biolayer interferometry, and their localization on sperm membranes was determined by immunofluorescence and immunoelectron microscopy. Western blot measured SgI-52 in seminal plasma and PRDX 6 on sperm membranes. Functional assays evaluated the effects of SgI-52 on PRDX 6 enzymatic activity, oxidative stress levels, and mitochondrial membrane potential in sperm.
resultsSgI-52 bound to PRDX 6 and co-localized on sperm membranes. Both seminal plasma SgI-52 and membrane-associated PRDX 6 were higher in AZS donors than in normal donors. Functional assays showed that SgI-52 inhibited PRDX 6 activity, leading to increased ROS and MDA levels and mitochondrial dysfunction in sperm.
conclusionIn vitro study, we observed differential expression of SgI-52 and PRDX6 in normal and AZS samples and revealed their interaction, explaining the preferential binding of SgI-52 to compromised sperm. These findings suggest that SgI-52–derived peptides could serve as molecular probes for sperm quality evaluation and sperm selection in assisted reproductive technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.